Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
about
The AP-2 family of transcription factorsActivator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated regionA phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerHistone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRMEstrogen-repressed genes -- key mediators of estrogen action?c-Src-null mice exhibit defects in normal mammary gland development and ERalpha signalingInverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complexTumor suppressor activity of AP2alpha mediated through a direct interaction with p53.Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1.HER2: biology, detection, and clinical implicationsBreaking the cycle: An insight into the role of ERα in eukaryotic cell cycles.Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancersActivator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review.Mechanisms of endocrine resistance in breast cancer.Estrogen represses gene expression through reconfiguring chromatin structures.Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancerAfatinib in the treatment of breast cancer.Downstream codons in the retinoic acid receptor beta -2 and beta -4 mRNAs initiate translation of a protein isoform that disrupts retinoid-activated transcription.Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin.Characterization of the human activator protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast tumour cells.Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells.Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.Membrane-bound estrogen receptor alpha initiated signaling is dynamin dependent in breast cancer cells.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
P2860
Q21184171-FAB81BD6-7417-4FEE-945A-147F4A0C366AQ24530625-52A9F9D2-BCB5-4BB7-B9A8-E6FC923CCA98Q24626194-C3475C15-A138-45B2-8FD7-BCDD4FB4C5E5Q24653898-C4D3AD52-AB88-4F19-AB62-C36BA8D79773Q24810826-72C3DC1D-7401-4048-A002-47FE0B946359Q28504741-902D4F73-EFB4-4B75-B7EE-3E917AD5E402Q31134061-165F58E1-FC27-4ED7-850A-4367BCF11654Q33701396-A8271C50-3EBF-4513-A103-7BF5AF56E1EAQ34149151-9E285B1D-E230-42E4-BD80-2A10EA55E8DBQ34306286-4D1E77D0-F93A-45F7-8D6C-1927CE56C7CBQ35558954-07B9602C-F0A3-4C00-87EE-96F86E2A5752Q35588055-9B009184-5710-4A2A-975D-3A8FCCC229A5Q35622862-CE3534BE-7974-4499-BD58-05A9C316E33DQ35624792-D1D7B662-E6B7-42D3-84B4-E82DE193298DQ35626357-74AC2108-633D-4CF7-B620-E3A2282C9E6DQ36671789-A787FDC0-CAFF-4073-B91E-A0E127E0ABBDQ36748207-14C817A2-42E9-4FE5-8D16-BC37F14B4A34Q36851417-A0F92C33-D248-4926-9821-2684AFE3F1E2Q37197796-0ABE66F6-B085-4FCE-985D-87ACDD56203EQ37255088-2518C6D5-BFA3-4FA9-BCAC-D865874F8B63Q37356307-BA340DEB-BD4D-4366-A03F-1AC63B2469BDQ38215591-18E71408-7BEF-467C-BC9F-D852D0E968D1Q38364206-19B876E0-08CF-4F04-8CB4-0130913DB2E6Q40076541-429CC708-3E01-4F81-AA53-33EE7DE008F7Q41965882-DA4AA74E-C467-4DCB-A856-FA6A9102DED1Q43968093-03A41E11-E580-4CBF-9BC1-2C7FADBF32F6Q44279198-B10C6314-A862-4C09-B0F5-5E153A1ABAB2Q54610139-0BA0E5B8-5F70-4C73-9A11-8D7522B5B3B1Q55283846-6B03430D-31C4-4089-B14D-4A2BB2673B51Q55479657-510AB781-A5EE-41B7-B135-F7BBD962AD9F
P2860
Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cofactor competition between t ...... 2 expression in breast cancer.
@ast
Cofactor competition between t ...... 2 expression in breast cancer.
@en
type
label
Cofactor competition between t ...... 2 expression in breast cancer.
@ast
Cofactor competition between t ...... 2 expression in breast cancer.
@en
prefLabel
Cofactor competition between t ...... 2 expression in breast cancer.
@ast
Cofactor competition between t ...... 2 expression in breast cancer.
@en
P2093
P2860
P356
P1433
P1476
Cofactor competition between t ...... 2 expression in breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203416
P407
P577
2000-01-01T00:00:00Z
P5875
P6179
1018302769